ICLR - ICON PLC - Stock Price & Dividends
Exchange: USA Stocks • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE0005711209
Clinical Trials, Laboratory Services, Consulting Services, Commercialization Services
ICON Public Limited Company is a leading clinical research organization that provides a comprehensive range of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations.
The company's expertise spans the entire clinical development process, from compound selection to Phase I-IV clinical studies, offering strategic development, management, and analysis of programs that support various stages of clinical development. This includes clinical development services, such as all phases of development, peri and post approval, data solutions, and site and patient access services.
ICON also provides clinical trial management, consulting, and contract staffing services, as well as commercial services that encompass clinical development strategy, planning and trial design, full study execution, and post-market commercialization. Additionally, the company offers a range of laboratory services, including bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers.
The company's extensive portfolio of services also includes adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real-world intelligence, site and patient, and strategic solutions.
With a strong presence in Ireland, rest of Europe, the United States, and internationally, ICON Public Limited Company has been a trusted partner to the life sciences industry since its incorporation in 1990. Headquartered in Dublin, Ireland, the company continues to drive innovation and excellence in clinical research and development.
For more information, please visit https://www.iconplc.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
ICLR Stock Overview
Market Cap in USD | 23,478m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC SubIndustry | Life Sciences Tools & Services |
TER | 0.00% |
IPO / Inception | 1998-05-15 |
ICLR Stock Ratings
Growth 5y | 50.6 |
Fundamental | 45.6 |
Dividend | |
Rel. Performance vs Sector | -2.63 |
Analysts | 4.56/5 |
Fair Price Momentum | 257.38 USD |
Fair Price DCF | 293.12 USD |
ICLR Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
ICLR Growth Ratios
Growth Correlation 3m | -82.2% |
Growth Correlation 12m | 43.8% |
Growth Correlation 5y | 78.3% |
CAGR 5y | 9.42% |
CAGR/Mean DD 5y | 0.64 |
Sharpe Ratio 12m | -0.04 |
Alpha vs SP500 12m | -53.28 |
Beta vs SP500 5y weekly | 1.23 |
ValueRay RSI | 3.20 |
Volatility GJR Garch 1y | 34.33% |
Price / SMA 50 | -22.11% |
Price / SMA 200 | -24.91% |
Current Volume | 2292.6k |
Average Volume 20d | 1136.5k |
External Links for ICLR Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of October 29, 2024, the stock is trading at USD 230.50 with a total of 2,292,577 shares traded.
Over the past week, the price has changed by -20.14%, over one month by -19.30%, over three months by -30.01% and over the past year by -5.52%.
According to ValueRays Forecast Model, ICLR ICON PLC will be worth about 285.3 in October 2025. The stock is currently trading at 230.50. This means that the stock has a potential upside of +23.79%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 356.1 | 54.5 |
Analysts Target Price | 278.8 | 21.0 |
ValueRay Target Price | 285.3 | 23.8 |